FDA decision to restrict ESAs may boost business for Cerus

09/15/2008 | East Bay (Calif.) Business Times

The FDA's decision to restrict the use of erythropoiesis-stimulating agents in cancer patients with anemia likely will boost the number of blood transfusions in the U.S., said Dr. Laurence Corash, chief medical officer of Cerus Corp. The change is expected to increase demand for the company's products, including the Intercept blood-safety system, which has yet to obtain FDA approval.

View Full Article in:

East Bay (Calif.) Business Times

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA